Clinical trials: MCI-AD, Early Stage Alzheimer's Disease
MCI-AD, Early Stage Alzheimer's Disease, Alzheimer s Disease
Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study
This proof-of-concept study explores whether long-term home-based closed-loop auditory stimulation during sleep enhances slow-wave activity (SWA) and yields preliminary efficacy signals in patients with amnestic mild cognitive…
- Conditions
- MCI-AD, Early Stage Alzheimer's Disease, Alzheimer s Disease, Mild Cognitive Impairment (MCI) Amnestic, AD
- Trial name
- Nana-Home (NCT07672977)
- Testing
- Closed-Loop Auditory Stimulation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bitbrain
Alzheimer s Disease, Alzheimer Dementia (AD)
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab.
- Conditions
- Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease
- Trial name
- NCT07604896
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Alzheimer Disease (AD), Alzheimer Dementia
Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice
This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment.
- Conditions
- Alzheimer Disease (AD), Alzheimer Dementia, MCI-AD, Early Stage Alzheimer's Disease
- Trial name
- NCT07505095
- Testing
- Lecanemab 10 mg/kg, Lecanemab 5-10mg/kg
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
MCI-AD, Early Stage Alzheimer's Disease
Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI
As populations age, Alzheimer's disease (AD) is increasing while disease-modifying drugs remain elusive, making early diagnosis and intervention essential.
- Trial name
- NCT07196592
- Testing
- Olfactory stimulation, Temporal Interference,TI, Olfactory-TI Stimulation
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Yuan Shen
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
MCI, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
The goal of this clinical trial is to assess the degree of improvement in cognitive functions, including memory, attention, thinking, executive and language functions in diagnosed patients MCI and AD taking dimethyl fumarate 480…
- Conditions
- MCI, MCI-AD, Early Stage Alzheimer's Disease, Alzheimer's Disease
- Trial name
- NCT06850597
- Testing
- dimethyl fumarate
- Where
- Poland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
A Diagnostic Test for Dementia With Lewy Bodies
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between…
- Trial name
- NCT05479552
- Testing
- Syn-One Test
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- CND Life Sciences